Memorial Sloan Kettering medical oncologist Isabel Preeshagul

Isabel Preeshagul, DO, MBS

Thoracic Oncologist

My Role at MSK

Areas of Expertise

My Specialties

  • Lung Cancer

Request an Appointment

Our Care Advisors can answer many of your questions. They will connect you with the best healthcare provider for your needs.
English
Share

About Me

What I Do at MSK
  • Assistant Attending Physician
Get To Know Me

I am a medical oncologist who specializes in caring for people with lung cancer. As an active member of the Thoracic Disease Management Team, I collaborate with specialties including radiation oncology, thoracic surgery, pathology, and interventional radiology. Together, we ensure that we provide extraordinary individualized care. My colleagues and I are committed to addressing not only each person’s disease, but also their unique social circumstances, priorities, and beliefs.

I am particularly interested in using precision medicine when planning treatment. This personalized approach allows us to provide the highest quality of care all closer to home at MSK Bergen, where I practice.

Read more

At all of MSK’s locations, people with lung cancer have a variety of treatment options and, if eligible, can participate in cutting-edge clinical trials. These studies take many forms, but all are directed toward learning more about their disease. MSK is leading the way in using precision medicine to select the most appropriate therapy based on the characteristics of your cancer. One size does not fit all and we take pride in offering each of our patients a comprehensive treatment plan designed just for them.

My research focuses on personalized medicine and using biomarkers to predict a person’s response to a treatment. By identifying these unique targets, we can select treatments that may be more effective. Knowing what the best treatment is for a particular person can minimize their exposure to toxicity from therapies that may be less beneficial to them. I have presented this work both nationally and internationally and continue to collaborate with my colleagues from multiple disciplines to advance this growing field.

I aim to ensure that my patients are an integral part of their treatment team. My goal is for them to feel supported and in control. I will continue my joint research efforts to provide better outcomes and improved quality of life for our patients.

My Role at MSK

A thoracic oncologist is a cancer doctor with special training in thoracic (thor-A-sik) cancers. These are cancers that have to do with the chest, including lung, tracheal (windpipe), and thymic (thymus) cancers.

Areas of Expertise

My Specialties

  • Lung Cancer
Education & Honors

Education

  • DO, Lake Erie College of Osteopathic Medicine
  • MBS, Rutgers University School of Biomedical Sciences

Residencies

  • Internal Medicine – Icahn School of Medicine at Mount Sinai-Mount Sinai Beth Israel

Awards and Honors

  • Chair, Patient Education and Engagement Committee for the Lung Cancer Research Foundation (2022-present)
  • Host, “Together Separately” webinar, Lung Cancer Research Foundation (2022-present)
  • Keynote Speaker at Relay for Life-FLOW (2018)
  • Peer-Nominated Patient Care Award, North Shore University Hospital-Long Island Jewish Medical Center-Northwell Health (2018)
  • Chief Hematology Oncology Fellow (2017-2018)

Fellowships

  • Hematology/Oncology – North Shore University Hospital-Long Island Jewish Medical Center-Northwell Health

Board Certifications

  • Internal Medicine
  • Medical Oncology

Insurance Information

Understanding your insurance options is an important part of managing your cancer care. We have relationships with many common healthcare providers and plans.

Aetna

In Network Coverage Type
HMO, EPO PPO, POS, Transplant

Aetna Medicare Advantage (MTA retirees only)

In Network Coverage Type
PPO

Blue Cross Blue Shield Federal Employee Program

In Network Coverage Type
HMO, PPO

Blue Cross Blue Shield New York

In Network Coverage Type
PPO, POS, EPO, HMO

Blue Cross Blue Shield states outside of NY/NJ

In Network Coverage Type
HMO, EPO PPO, POS

Blue Cross Health Plus

In Network Coverage Type
HMO

Carrum Health

In Network Coverage Type
Supplemental

Cigna

In Network Coverage Type
PPO, POS, HMO

MSK has a tentative agreement with Cigna to continue coverage in 2024.

Connecticare

In Network Coverage Type
POS, EPO, HMO

Emblem

In Network Coverage Type
PPO, POS, EPO, HMO

Emblem Essential

In Network Coverage Type
HMO

Emblem Medicare Advantage

In Network Coverage Type
PPO, HMO

Empire Blue Cross Medicare Advantage

In Network Coverage Type
PPO, HMO, DSN

Empire Essential

In Network Coverage Type
HMO

Empire Plan / NYSHIP (Blue Cross/UnitedHealthcare split plan)

In Network Coverage Type
PPO

Fidelis

In Network Coverage Type
HMO, EPO

Fidelis Managed Medicaid & HARP

In Network Coverage Type
HMO

Fidelis Medicare Advantage

In Network Coverage Type
HMO

First Health

In Network Coverage Type
PPO

Healthfirst

In Network Coverage Type
EPO, HMO, PPO, POS

Healthfirst Managed Medicaid

In Network Coverage Type
HMO

Healthfirst Medicare Advantage

In Network Coverage Type
HMO, PPO

Healthsmart

In Network Coverage Type
PPO EPO

Horizon Blue Cross Blue Shield New Jersey (HMO)

In Network Coverage Type
HMO

Horizon Blue Cross Blue Shield New Jersey (PPO)

In Network Coverage Type
PPO

Horizon Blue Cross Blue Shield New Jersey Omnia Tier I (EPO)

In Network Coverage Type
EPO

Horizon Blue Cross Blue Shield New Jersey Omnia Tier II (EPO)

In Network Coverage Type
EPO

Horizon Medicare Advantage

In Network Coverage Type
PPO, HMO

Husky CT Medicaid

In Network Coverage Type
State Government

Magnacare

In Network Coverage Type
PPO, POS, EPO

Straight NJ Medicaid

In Network Coverage Type
State Government

Straight NY Medicaid

In Network Coverage Type
State Government

Medicare Part A&B (traditional Medicare)

In Network Coverage Type
Federal Government

Multiplan/Beech Street/PHCS

In Network Coverage Type
Supplemental

MVP

In Network Coverage Type
PPO/OAP

Non-Participating Plans with Out of Network Benefits

In Network Coverage Type
PPO, POS, EPO, HMO

NYC Medicare Advantage Plus for City Employees

In Network Coverage Type
TBD

Oscar

In Network Coverage Type
HMO/EPO

Oxford

In Network Coverage Type
PPO, EPO

World Trade Center Health Program (WTC)

In Network Coverage Type
State Government

Qualcare

In Network Coverage Type
PPO, POS, HMO

Tricare

In Network Coverage Type
PPO, HMO

UMR

In Network Coverage Type
PPO, POS

United Healthcare

In Network Coverage Type
PPO, POS, HMO

Don't see your carrier or plan? We can help you understand your coverage.

If you don't have health insurance or are worried that your care may not be fully covered, our financial assistance programs may be able to help.

If you have questions about insurance, call us at 646-497-9176.

Make an Appointment

Current Patients

Request an appointment by logging on to MyMSK or calling your doctor’s office. If you aren’t registered for MyMSK, call 646-227-2593 for your Enrollment ID.

Contact and Location

Dr. Preeshagul sees patients at one location.

Office Phone
Location
Montvale, NJ
225 Summit Avenue Montvale NJ 07645

Looking to see a doctor at a different location? See all MSK locations.

Colleagues

Doctors at Memorial Sloan Kettering work as teams, with specialists from all different areas. This allows us to consider all your needs together, and to give you the best possible care.

See all Thoracic Oncology Service doctors

Clinical Trials

Smiling doctors in the lab
Find a Clinical Trial for You

Memorial Sloan Kettering's doctors and scientists are constantly developing new treatments for cancer. MSK is typically running hundreds of clinical trials at a given time.

You may be able to participate in a clinical trial even if you are new to MSK. Search our online directory to find trial information and see more about who can participate.

Search clinical trials

Research and Publications

Mezquita L, Preeshagul I, Auclin E, Saravia D, Hendriks L, Rizvi H, Park W, Nadal E, Martin-Romano P, Ruffinelli JC, Ponce S, Audigier-Valette C, Carnio S, Blanc-Durand F, Bironzo P, Tabbò F, Reale ML, Novello S, Hellmann MD, Sawan P, Girshman J, Plodkowski AJ, Zalcman G, Majem M, Charrier M, Naigeon M, Rossoni C, Mariniello A, Paz-Ares L, Dingemans AM, Planchard D, Cozic N, Cassard L, Lopes G, Chaput N, Arbour K, Besse B. Predicting immunotherapy outcomes under therapy in patients with advanced NSCLC using dNLR and its early dynamics. Eur J Cancer. 2021 Jul;151:211-220. doi: 10.1016/j.ejca.2021.03.011. Epub 2021 May 19. PMID: 34022698.

Thor M, Shepherd AF, Preeshagul I, Offin M, Gelblum DY, Wu AJ, Apte A, Simone CB 2nd, Hellmann MD, Rimner A, Chaft JE, Gomez DR, Deasy JO, Shaverdian N. Pre-treatment immune status predicts disease control in NSCLCs treated with chemoradiation and durvalumabRadiother Oncol. 2022 Feb;167:158-164. doi: 10.1016/j.radonc.2021.12.016. Epub 2021 Dec 20. PMID: 34942280; PMCID: PMC9518843.

Luo J, Rizvi H, Egger JV, Preeshagul IR, Wolchok JD, Hellmann MD. Impact of PD-1 Blockade on Severity of COVID-19 in Patients with Lung Cancers. Cancer Discov. 2020 Aug;10(8):1121-1128. doi: 10.1158/2159-8290.CD-20-0596. Epub 2020 May 12. Erratum in: Cancer Discov. 2021 Feb;11(2):520. PMID: 32398243; PMCID: PMC7416461.

Read more

Luo J, Rizvi H, Egger JV, Preeshagul IR, Wolchok JD, Hellmann MD. Impact of PD-1 Blockade on Severity of COVID-19 in Patients with Lung Cancers. Cancer Discov. 2020 Aug;10(8):1121-1128. doi: 10.1158/2159-8290.CD-20-0596. Epub 2020 May 12. Erratum in: Cancer Discov. 2021 Feb;11(2):520. PMID: 32398243; PMCID: PMC7416461.

Seetharamu N, Preeshagul I, Sullivan K. New PDL-1 Inhibitors In NSCLC - Impact of Atezolizumab. Lung Cancer Targets and Therapy. 2017 July;13 (8): 67-78.

Sullivan K, Preeshagul I, Budman D, Seetharamu N. Immune checkpoint inhibitors in lung cancer: an update. Future Oncol. 2017 May;13(11):955-959. doi: 10.2217/fon-2017-0044. PMID: 28481150.

Saxena A, Becker D, Preeshagul I, Lee K, Katz E, Levy B. Therapeutic Effects of Repurposed Therapies in Non-Small Cell Lung Cancer: What Is Old Is New Again. Oncologist. 2015 Aug;20(8):934-45. doi: 10.1634/theoncologist.2015-0064. Epub 2015 Jul 8. PMID: 26156329; PMCID: PMC4524771.

Publications on PubMed

Visit PubMed for a full listing of Dr. Preeshagul’s journal articles. Pubmed is an online index of research papers and other articles from the US National Library of Medicine and the National Institutes of Health.

See all on PubMed

Disclosures

Doctors and faculty members often work with pharmaceutical, device, biotechnology, and life sciences companies, and other organizations outside of MSK, to find safe and effective cancer treatments, to improve patient care, and to educate the health care community.

MSK requires doctors and faculty members to report (“disclose”) the relationships and financial interests they have with external entities. As a commitment to transparency with our community, we make that information available to the public.

Isabel Preeshagul discloses the following relationships and financial interests:

  • Aptitude Health
    Professional Services and Activities
  • AstraZeneca
    Professional Services and Activities
  • Boehringer Ingelheim
    Professional Services and Activities (Uncompensated)
  • Dava Oncology
    Professional Services and Activities
  • G1 Therapeutics
    Professional Services and Activities
  • Genentech
    Professional Services and Activities
  • Jazz Pharmaceuticals
    Professional Services and Activities
  • LabCorp
    Professional Services and Activities
  • Novartis
    Professional Services and Activities
  • Pfizer, Inc.
    Professional Services and Activities
  • Takeda Pharmaceuticals
    Professional Services and Activities

If you’re a patient at MSK and would like more information about your doctor’s external relationships, please talk with your doctor.

The information published here is for a specific annual disclosure period. There may be differences between information on this and other public sites as a result of different reporting periods and/or the various ways relationships and financial interests are categorized by organizations that publish such data.


This page and data include information for a specific MSK annual disclosure period (January 1, 2022 through disclosure submission in spring 2023). This data reflects interests that may or may not still exist. This data is updated annually.

Learn more about MSK’s COI policies here. For questions regarding MSK’s COI-related policies and procedures, email MSK’s Compliance Office at [email protected].


View all disclosures